IQVIA Holdings Inc. to Announce First-Quarter 2025 Results

IQVIA Holdings Inc. (NYSE:IQV), a prominent player in the healthcare and life sciences sectors, has announced that it will disclose its first-quarter 2025 financial results on May 6, 2025. The release will occur before the market opens, allowing investors and analysts to evaluate the company's performance early in the trading day.

In conjunction with the earnings release, IQVIA's management team will host a conference call and webcast at 9:00 a.m. Eastern Time on the same day. This event will provide an opportunity for stakeholders to hear directly from company executives regarding the quarter’s performance, strategic initiatives, and future outlook.

To join the conference call, interested parties are required to register in advance via a provided link. Following registration, participants will receive a confirmation email containing details necessary to join the call, including a unique passcode and registrant ID. This ensures a streamlined process for accessing the live discussion.

For those unable to attend the live event, a replay of the webcast will be accessible approximately two hours after its conclusion on the IQVIA Investor Relations website.

IQVIA stands at the forefront of clinical research services and healthcare intelligence, delivering critical insights to the life sciences industry. Leveraging its proprietary IQVIA Connected Intelligence™ platform, the company offers solutions built on high-quality health data, advanced analytics, and healthcare-grade AI technology. With a workforce of approximately 88,000 employees spread across more than 100 countries, IQVIA is positioned as a leader in accelerating the development and commercialization of innovative medical treatments.

IQVIA emphasizes its commitment to patient privacy and ethical practices in artificial intelligence. The company employs a variety of privacy-enhancing technologies to safeguard individual data while analyzing information at scale. This approach allows healthcare stakeholders to identify disease patterns and optimize treatment pathways, ultimately aiming for improved patient outcomes and population health.

The insights generated by IQVIA enable biotech, pharmaceutical companies, medical device manufacturers, and government agencies to deepen their understanding of diseases and human behaviors. Through its innovative solutions, IQVIA plays a crucial role in advancing the healthcare landscape, supporting stakeholders in their pursuit of effective therapies and cures.

As the May 6 announcement approaches, market participants will be keen to assess IQVIA's performance in the first quarter of 2025. The upcoming conference call is expected to provide valuable insights into the company's strategies and future direction in the rapidly evolving healthcare sector. For additional information, stakeholders can visit the IQVIA Investor Relations website.